Anti-CD19 CAR NK Cell therapy (Enricnk)

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameAnti-CD19 CAR NK Cell therapy (Enricnk)
Drug Alias NameAnti-CD19 Chimeric Antigen Receptor (CAR) Nature Killer Cells Therapy(Enricnk)Anti-CD19 CAR NK-cell therapy(Enricnk)Anti-CD19 CAR NK cells therapy (Rui Therapeutics)CD19 Chimeric Antigen Receptor NK Cell therapy (Rui Therapeutics)CD19 CAR NK Cells therapy (Rui Therapeutics) +[7] 
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAnti-synthetase SyndromeAutoimmune DiseasesScleroderma, Systemic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Rui Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Rui Therapeutics Co LtdChanghai Hospital
Inactive CompaniesN/A
Active IndicationsAnti-synthetase SyndromeAutoimmune DiseasesScleroderma, Systemic +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A